A new diagnostic tool developed at the University of Tennessee Health Sciences may soon make it significantly easier for physicians to detect cardiac amyloidosis, a progressive and frequently underdiagnosed disease caused by abnormal protein deposits in the heart.
The tool is a novel imaging technology, a radioactive molecule that, when injected into a patient and scanned, lights up amyloid deposits in the heart, making a disease that was once nearly invisible on imaging clearly visible for the first time.
Bayer announced on May 7, 2026, that the Phase 3 REVEAL study — a large, multisite clinical trial evaluating the molecule’s performance — confirmed that the investigational PET imaging tracer iodine-124 evuzamitide detected cardiac amyloidosis with strong sensitivity and specificity in patients with suspected disease. The tracer was evaluated across 19 U.S. centers against standard clinical diagnosis methods.